Australia - engelsk - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 0.16 g/g; cannabidiol, quantity: 0.01 g/g - herb, dried - excipient ingredients: air - there is growing evidence that medicinal cannabis may have a role in several medical conditions. these include intractable chronic pain insufficiently responsive to other analgesics, pain associated with spasticity in multiple sclerosis (ms), pain associated with cancer in palliative care, nausea and vomiting caused by cancer treatment, appetite loss, sleep disturbance, post-traumatic stress disorder (ptsd), body wasting. your doctor may have prescribed lgp medicinal cannabis dried flower for another reason.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 0.18 g/g; cannabidiol, quantity: 0.01 g/g - herb, dried - excipient ingredients: air - there is growing evidence that medicinal cannabis may have a role in several medical conditions. these include intractable chronic pain insufficiently responsive to other analgesics, pain associated with spasticity in multiple sclerosis (ms), pain associated with cancer in palliative care, nausea and vomiting caused by cancer treatment, appetite loss, sleep disturbance, post-traumatic stress disorder (ptsd), body wasting. your doctor may have prescribed lgp medicinal cannabis dried flower for another reason.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 0.2 g/g; cannabidiol, quantity: 0.01 g/g - herb, dried - excipient ingredients: air - there is growing evidence that medicinal cannabis may have a role in several medical conditions. these include intractable chronic pain insufficiently responsive to other analgesics, pain associated with spasticity in multiple sclerosis (ms), pain associated with cancer in palliative care, nausea and vomiting caused by cancer treatment, appetite loss, sleep disturbance, post-traumatic stress disorder (ptsd), body wasting. your doctor may have prescribed lgp medicinal cannabis dried flower for another reason.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 0.22 g/g; cannabidiol, quantity: 0.01 g/g - herb, dried - excipient ingredients: air - there is growing evidence that medicinal cannabis may have a role in several medical conditions. these include intractable chronic pain insufficiently responsive to other analgesics, pain associated with spasticity in multiple sclerosis (ms), pain associated with cancer in palliative care, nausea and vomiting caused by cancer treatment, appetite loss, sleep disturbance, post-traumatic stress disorder (ptsd), body wasting. your doctor may have prescribed lgp medicinal cannabis dried flower for another reason.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 0.24 g/g; cannabidiol, quantity: 0.01 g/g - herb, dried - excipient ingredients: air - there is growing evidence that medicinal cannabis may have a role in several medical conditions. these include intractable chronic pain insufficiently responsive to other analgesics, pain associated with spasticity in multiple sclerosis (ms), pain associated with cancer in palliative care, nausea and vomiting caused by cancer treatment, appetite loss, sleep disturbance, post-traumatic stress disorder (ptsd), body wasting. your doctor may have prescribed lgp medicinal cannabis dried flower for another reason.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - tetrahydrocannabinol, quantity: 1 mg/ml; cannabidiol, quantity: 100 mg/ml - oral liquid - excipient ingredients: - there is growing evidence that medicinal cannabis may have a role in treating the symptoms of many medical conditions. these include chronic pain, spasticity and pain in multiple sclerosis (ms), pain associated with cancer in palliative care, nausea and vomiting caused by cancer treatment, appetite loss, sleep disturbance, post-traumatic stress disorder (ptsd), body wasting, anxiety and drug-resistant epilepsy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604.1 mg (equivalent: pemetrexed, qty 500 mg) - injection, concentrated - excipient ingredients: trometamol; hydrochloric acid; sodium hydroxide; water for injections; monothioglycerol; citric acid - malignant pleural mesothelioma,pemetrexed ever pharma, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed ever pharma in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed ever pharma as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - pemetrexed disodium hemipentahydrate, quantity: 1208.21 mg (equivalent: pemetrexed, qty 1000 mg) - injection, concentrated - excipient ingredients: trometamol; hydrochloric acid; sodium hydroxide; water for injections; monothioglycerol; citric acid - malignant pleural mesothelioma,pemetrexed ever pharma, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed ever pharma in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed ever pharma as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.82 mg (equivalent: pemetrexed, qty 100 mg) - injection, concentrated - excipient ingredients: trometamol; hydrochloric acid; sodium hydroxide; water for injections; monothioglycerol; citric acid - malignant pleural mesothelioma,pemetrexed ever pharma, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed ever pharma in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed ever pharma as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Israel - engelsk - Ministry of Health

padagis israel pharmaceuticals ltd, israel - bifonazole; fluocinonide - cream - fluocinonide 0.05 w/w; bifonazole 1.00 w/w - bifonazole - bifonazole - broad-spectrum drug for relief of inflammatory conditions accompanied by fungal infection, which respond to corticoid therapy.